Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097968
Status:
COMPLETED
Last Update Posted:
2010-07-12
First Post:
2004-12-01
Brief Title:
SafetyEfficacy of Everolimus and Neoral in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-Label Single Arm Pilot Study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients With Established Allograft Vasculopathy
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation
It is usually used in combination with other immunosuppressive drugs such as cyclosporine The purpose of this study is to evaluate the change in kidney function after beginning everolimus while determining the most effective Neoral cyclosporine dose to take with everolimus in adult cardiac transplant patients who have had their transplanted heart for at least 1 year and who have cardiac allograft vasculopathy
It is usually used in combination with other immunosuppressive drugs such as cyclosporine The purpose of this study is to evaluate the change in kidney function after beginning everolimus while determining the most effective Neoral cyclosporine dose to take with everolimus in adult cardiac transplant patients who have had their transplanted heart for at least 1 year and who have cardiac allograft vasculopathy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RADCertican | None | None | None |